Protein depletion is a key approach to understanding the functions of a protein in a biological system. We recently developed the Trim-Away approach in order to rapidly degrade endogenous proteins without prior modification. TrimAway is based on the ubiquitin ligase and Fc receptor TRIM21, which recognizes antibody-bound proteins and targets them for degradation by the proteasome. In a typical Trim-Away experiment, protein degradation is achieved in three steps: first, introduction of an antibody against the target protein; second, recruitment of endogenous or exogenous/ overexpressed TRIM21 to the antibody-bound target protein; and third, proteasome-mediated degradation of the target protein, antibody and TRIM21 complex. Protein degradation by Trim-Away is acute and rapid, with half-lives of 10-20 min. The major advantages of Trim-Away over other protein degradation methods are that it can be applied to any endogenous protein without prior modification; that it uses conventional antibodies that are widely available; and that it can be applied to a wide range of cell types, including nondividing primary human cells, for which other loss-of-function assays are challenging. In this protocol, we describe the detailed procedures for antibody preparation and delivery in mouse oocytes and cultured cells via microinjection and electroporation. In addition, we provide recommendations for antibody selection and validation, and for the generation of TRIM21-overexpressing cell lines for cases in which endogenous TRIM21 is limited. A typical Trim-Away experiment takes just a few hours.
Introduction
Protein depletion is one of the key tools used in studying protein functions in cells and tissues, and can be achieved by either interfering with protein synthesis or inducing protein degradation. Protein synthesis can be blocked at various levels. At the genomic level, protein-coding genes can be disrupted using genome-editing technologies such as zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases and the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas system. All these technologies are based on nucleases that can be targeted to a specific DNA sequence and introduce a frameshift mutation or a premature stop codon, or delete the coding sequence 1 . At the post-transcriptional level, messenger RNAs (mRNAs) can be targeted for degradation using RNA interference (RNAi). To this end, sequence-specific small interfering RNAs or short hairpin RNAs are introduced into cells. These are incorporated into RNA-induced silencing complexes, which bind to and degrade the target mRNA 2 . At the translational level, morpholino oligomers can be used to block the translation of mRNAs. These antisense oligonucleotides bind to the target mRNA and block the progression of the translation initiation complex from the 5′ cap to the start codon 3 . Although these techniques have been proven to be highly useful for studying various genes in different model systems, a common major limitation is that they are not suitable to deplete alreadysynthesized proteins. In both metabolically inactive and long-lived metabolically active cells, certain proteins-particularly those in essential cellular structures-can persist for years after translation 4 . These long-lived proteins cannot be depleted by blocking protein synthesis at the gene or mRNA level. Another limitation of methods that act at the gene or mRNA level is the long delay between the time of their application and actual protein depletion, which is typically in the range of days. These methods are therefore not well suited to investigating short-lived biological processes. For example, many regulatory proteins have multiple functions during different stages of mitosis, which takes onlỹ 1 h in HeLa cells 5 . If protein degradation is delayed, it is difficult to determine whether the phenotypes are a direct consequence of protein depletion or a secondary consequence of earlier defects 6 . Delays may also allow cells to activate compensatory mechanisms, which may modify or even mask the phenotypes 7 . To overcome these challenges, several methods have been developed that act directly at the protein level, targeting the protein itself for degradation. Some of these methods are based on controlling protein stability, for instance, by fusing the target protein to destabilizing domains that are controlled by ligands 8, 9 . Others are based on recruiting SKP1-CUL1-F-box (SCF) E3 ubiquitin ligases to the target protein, such as the binding of an auxin-inducible degron to the F-box protein TIR1 and the binding of GFP-tagged proteins to a GFP nanobody fused to the F-box domain of Slmb 10, 11 . Proteins can also be perturbed acutely by knock-sideways approaches, in which proteins are targeted away from their principal site of action, for instance, by tethering them to mitochondria 12 . However, all of these assays require the endogenous protein to be first replaced by a modified variant. Hence, they are not suitable for studying protein functions in all cell types. For instance, application of these methods in nondividing primary cells would often require the generation of transgenic animals. This is time consuming and not feasible for many species. For tag-free degradation, ligand-and peptide-based techniques have been developed, but the number of proteins that can be targeted with these methods is very limited 13, 14 . To achieve acute depletion of any endogenous protein without prior modification, we recently developed a post-translational protein depletion method, which we called 'Trim-Away' 15 . Trim-Away relies on an E3 ubiquitin ligase called TRIM21 (ref. 16 ). TRIM21 is involved in the intracellular immune response; it binds to antibody-bound pathogens and proteopathic agents and targets them for degradation [17] [18] [19] . The precise mode of action of TRIM21 is not yet fully understood, but it involves binding of TRIM21 to the Fc-region of an antibody and subsequent autoubiquitination of TRIM21. In a Trim-Away experiment, the high affinity of TRIM21 to the Fc-region of an antibody is exploited to target endogenous proteins for degradation. An antibody against the target protein is introduced, and TRIM21 binds to the antibody-bound target protein and triggers the proteasomemediated degradation of the antibody-antigen complex together with TRIM21 (refs. 20, 21 ). TrimAway has enabled us to degrade a wide variety of proteins within minutes of application in different cell types 15 . For instance, we could acutely deplete Rec8 in unmodified mouse oocytes 15 , an experiment that required complex genetics in the past 22 . We have also been able to deplete the intracellular signaling molecule NLRP3 in human primary macrophages, which was not possible in the past with nucleic acid-based depletion techniques 15 . Here, we (i) describe the design of TrimAway experiments; (ii) detail the selection and preparation of reagents for Trim-Away experiments; (iii) discuss the procedures for use of Trim-Away in mouse oocytes and pre-implantation embryos; (iv) present the procedures for use of Trim-Away in primary cells and cell lines; and (v) propose quality controls for Trim-Away experiments. We also highlight and give advice on critical steps in the Procedure.
Overview of the procedure
For a successful Trim-Away experiment, a specific antibody that targets an intracellular protein of interest must be delivered into cells that contain TRIM21. If the endogenous levels of TRIM21 are not sufficient for protein degradation, TRIM21 must also be introduced together with or before antibody delivery. In this protocol, we outline different methods for introducing antibody and TRIM21 into cells and give advice on how to preselect specific antibodies for a successful Trim-Away experiment. A routine Trim-Away experiment involves the following three events ( Fig. 1 ): 1 Ensuring sufficient TRIM21 levels in target cells of interest. TRIM21 is widely expressed in different cell types 23 . Depending on the expression level of the target protein, endogenous TRIM21 levels may be sufficient for Trim-Away 15 . But as TRIM21 is continuously degraded during a Trim-Away experiment and typically not expressed at high levels, the endogenous level may be insufficient for complete target protein degradation. Additional TRIM21 can be introduced in the form of a transgene (i.e., DNA), mRNA or protein. Using TRIM21-encoding DNA, we have transiently transfected cell lines or created stable lines with a TRIM21 expression cassette integrated into their genomes 15 (see also Box 1) . Stable lines simplify the workflow in a Trim-Away experiment because only the delivery of the antibody is required for acute protein degradation. In certain cases, cells with low expression levels of TRIM21 must be preselected by FACS because high expression of TRIM21 can sometimes lead to the formation of protein aggregates, which are nonfunctional 15 . We have also used in vitro-transcribed mRNAs to transiently express TRIM21 in mouse oocytes 15 . Using mRNAs accelerates the expression of TRIM21 and allows fine-tuning of the expression level, but translation rates may vary for cells at different cell cycle stages. TRIM21 can also be introduced in the form of a recombinant protein, for instance, by electroporation 15 . Recombinant TRIM21 (see also Box 2) eliminates the incubation time that is required for protein expression from DNA or mRNA before a Trim-Away experiment. However, recombinant TRIM21 can be exhausted if not replenished. 2 Delivery of antibody. Depending on the experimental setup, the antibody can be delivered by either microinjection (Step 16) or electroporation (Steps 17-32). We have microinjected antibody into mouse oocytes and single adherent cells 15 . Microinjection allows tight control over the amount of antibody delivered into each cell and is the method of choice when individual cells must be analyzed rapidly upon triggering protein degradation. For bulk cell populations, we recommend delivering the antibody by electroporation using the Neon Transfection System 15 . Unlike protein transfection reagents, electroporation can be used to simultaneously deliver the antibody into the cytoplasm of many cells without antibody accumulation in the endosome and/or lysosome. In addition to conventional antibodies, we have also used a fusion between a nanobody and the Fc-region of human IgG1 for protein degradation by Trim-Away 15 . We have introduced this nanobody-Fc fusion into mouse oocytes as mRNA, but delivery as DNA or protein into other cell types should work as well 15 . 3 Target protein degradation. When the antibody has bound to the target protein, TRIM21 targets the antibody-antigen complex for degradation via the ubiquitin-proteasome pathway 20, 21 . Degradation typically starts within 5-10 min after application of the antibody 15 . Complete depletion can be achieved within~3 h, depending on the abundance and accessibility of the target protein, as well as the amount of antibody that was introduced into the cell 15 .
Applications of the method
Trim-Away uses TRIM21 to degrade endogenous proteins that are bound to an antibody. Our results suggest that any protein within a cell that is accessible by an antibody can be degraded by Trim-Away. Because TRIM21 proteins and antibodies are highly conserved among different mammalian species, Trim-Away works with a wide range of cells and antibodies 24 . Trim-Away acts very rapidly and does not require prior modification of the target protein. It also works in various cell types, including nondividing primary cells. Trim-Away also allows loss-of-function studies in primary immune cells, which could not be studied efficiently with nucleic acid-based depletion methods in the past.
Some specific examples of what can be studied are (i) the function of a protein within a defined cell cycle stage without affecting its other potential functions during the other cell cycle stages; (ii) the roles of proteins for the maintenance of cellular structures, even if these proteins are essential for the formation of these structures; (iii) the functions of the cytoplasmic pool of certain proteins; (iv) the functions of certain proteins with a particular post-translational modification; (v) the functions of specific isoforms of certain proteins; and (vi) structure-function relationships in certain proteins by depletion followed by rescue with different mutants. 
Box 1 | Preparation of TRIM21 stable cell lines • Timing 2-3 weeks
Although TRIM21 is nearly universally expressed, its expression level varies between cell types. Because TRIM21 is degraded alongside the antibody and target antigen during Trim-Away, levels of endogenous TRIM21 may be insufficient to elicit complete degradation of the target antigen, especially in cases in which the target antigen is abundant. This can be remedied by the constitutive expression of TRIM21 stably integrated into the target cell genome. Here, we describe a protocol for stable cell line generation by transduction with pseudotyped lentiviral particles. However, alternative approaches for stable cell line generation can also be used. 3 In a sterile 1.5-ml reaction tube, prepare 200 μl of Opti-MEM I, 2 μg of HIV GagPol expression plasmid (e.g., psPAX2), 2 μg of TRIM21 construct in lentiviral transfer vector (e.g., pSMPP-mCherry-hTRIM21) and 1 μg of VSV-G glycoprotein expression plasmid (e.g., pMD2.G). 4 Mix the plasmids well by gentle vortexing and bring to the bottom of the tube with a brief spin in a microcentrifuge (2,000g, 25°C, 5 s). 5 Add 12 µl of FuGENE 6 transfection reagent to the plasmids and mix immediately by flicking. Bring the liquid to the bottom of the tube with a brief spin in a microcentrifuge (2,000g, 25°C, 5 s). 6 Incubate the transfection mix for 20 min at room temperature. 7 Add the transfection mix dropwise to the center of the dish of HEK293T cells with gentle swirling. c CRITICAL STEP Mixing by pipetting or vigorous agitation should be avoided, as it may dislodge HEK293T cells from tissue culture dishes. 8 Incubate the cells for 16-24 h at 37°C in a 5% CO 2 atmosphere. 9 Gently remove the medium and replace with fresh, prewarmed DMEM supplemented with 1× GlutaMAX and 10% (vol/vol) FBS, and then return the cells to the incubator for a further 48 h. 10 (Optional) Examine the cells under a fluorescence microscope to ensure high levels of mCherry-hTRIM21 expression in virus-producing cells resulting from transfection and single-cycle re-infection. 11 Harvest the supernatant directly into a 10-ml syringe; then filter at 0.45 µm, separate into 1-ml aliquots and store the virus particles at −80°C. j PAUSE POINT Viral particles can be stored indefinitely at −80°C. 12 Seed adherent target cells at 1 × 10 5 per well in six-well plates in appropriate medium. Suspension cells can be seeded in 24-well plates in their normal medium with polybrene at 10 μg/ml and transduced immediately (step 15). 13 Incubate the cells for 16-24 h at 37°C in a 5% CO 2 atmosphere. 14 Replace the medium with fresh medium containing 10 μg/ml polybrene (2× final concentration). 15 Thaw the virus supernatant at room temperature. 16 On the first transduction of a new cell type, or after production of a new batch of virus supernatant, add virus at a range of concentrations to determine the optimal level for low-multiplicity transduction (<0.1 transducing particles per cell). Prepare a five-fold serial dilution of virus in medium such that successive wells will receive 1, 5, 25, 125 and 625 μl of virus. Add virus to cells in a volume equal to that of the plating medium such that the final polybrene concentration is 5 μg/ml. Include a control well that does not receive virus. 17 Incubate the cells for 48 h at 37°C in a 5% CO 2 atmosphere. 18 Analyze for transgene expression by fluorescence microscopy or flow cytometry. Select conditions in which <10% of cells are expressing mCherry-TRIM21, in order to minimize the number of multiply transduced cells. 19 Add puromycin to the cells at an appropriate concentration for the cell type, typically 0.5-5 µg/ml. 20 After 1 week of selection, all untransduced cells and the untreated control well should be killed. Expand the cell population for freezing and for use in Trim-Away experiments. c CRITICAL STEP Regularly ensure that the distribution of mCherry-TRIM21 is diffuse and cytoplasmic by fluorescence microscopy (Fig. 4b,e) . Large crescent-shaped aggregates of mCherry-TRIM21 that are nonfunctional can form if levels of expression are too high or cells become overconfluent. This seems to be a cell-type-specific phenomenon and occurs in cell types in which expression from viral promoters is particularly high, for instance, in HEK293 cells. In such a case, consider FACS-sorting low mCherry-positive cells or deriving clonal lines and selecting lowexpressing colonies. Alternatively, consider using a tetracycline-inducible promoter to drive TRIM21 expression.
Reagents

Box 2 | Preparation of recombinant TRIM21 protein (3 d)
This box describes the procedure for expression and purification of full-length human TRIM21 protein His-Lipoyl-hTRIM21 (Fig. 2g) . His-LipoylhTRIM21 is expressed from a T7-promoter-driven bacterial expression plasmid HLTV-hTRIM21. HLTV-hTRIM21 is available from Addgene (Reagents) and is a low copy-number ampicillin-resistant plasmid with an N-terminal His tag that can be optionally cleaved by TEV protease. 
Biological materials
Reagent setup
• 100 mg/ml ampicillin. Add 10 g of ampicillin sodium salt to 100 ml of sterile water. Filter at 0.45 µm. Divide into 10-ml aliquots and store at −20°C (for up to 1 year) until use.
• LB agar plates supplemented with 100 µg/ml ampicillin. Add 40 g of LB-Agar Miller to 1 L of sterile water. Autoclave at 120°C for 15 min. Cool down briefly and add 1 ml of 100 mg/ml ampicillin before pouring plates. Store at 4°C (for up to 3 months) until use.
• 2× TY medium. Add 31 g of 2× TY medium to 1 L of sterile water. Autoclave at 120°C for 15 min. Freshly prepare before use.
• 0.1 M IPTG. Add 2.38 g of IPTG to 100 ml of sterile water. Filter at 0.45 µm. Divide into 10-ml aliquots and store at −20°C (for up to 1 year) until use.
• 10% (wt/vol) glucose. Add 10 g of glucose to 100 ml of sterile water. Autoclave at 120°C for 15 min. Freshly prepare before use.
• 1 M Tris (pH 8.0). Add 12.1 g of Trizma base to 90 ml of sterile water. Adjust the pH to 8.0 and bring the final volume to 100 ml with sterile water.
Store at room temperature (for up to 1 year) until use.
• 5 M NaCl. Add 29.2 g of sodium chloride to 90 ml of sterile water. Bring the final volume to 100 ml with sterile water. Store at room temperature (for up to 1 year) until use.
• PBS (pH 8.0). Add 5 g of PBS tablet to 450 ml of sterile water. Adjust the pH to 8.0 and bring the final volume to 100 ml with sterile water. Store at room temperature (for up to 1 year) until use. Procedure 1 Freshly transform C41(DE3) cells with HLTV-hTRIM21, and plate the transformed cells onto a LB-agar plate supplemented with 100 µg/ml ampicillin overnight at 37°C. 2 Pick colonies and inoculate overnight cultures in 25 ml of 2× TY supplemented with 2% (wt/vol) glucose and 100 µg/ml ampicillin. Shake at 220 r.p.m. at 37°C. 3 Inoculate 1 liter of 2× TY medium with 10 ml of overnight culture, and supplement with 0.1% (wt/vol) glucose and 100 µg/ml ampicillin. Shake at 220 r.p.m. at 37°C. 4 At OD 600 0.8-1.2 (after~3 h), induce with 0.1 mM IPTG and reduce the temperature to 22°C. c CRITICAL STEP Induction at OD values >1.2 or overnight growth at higher temperatures will markedly reduce yields. 5 The next day, harvest the cells in 1-liter centrifuge bottles by centrifuging at 5,000g for 20 min at 4°C (e.g., using a RC3B rotor). Discard the medium. j PAUSE POINT Bacterial pellets can be frozen at −20°C and stored for up to 1 week, and protein preparation can be continued later. 
Advantages and limitations of the method
In comparison with other currently available protein depletion techniques, Trim-Away has several unique advantages. First, Trim-Away acts directly at the protein level. It is therefore effective against long-lived proteins, and the development of phenotypes does not rely on inherent turnover of the target protein. Second, Trim-Away does not require modification of the genome. It therefore greatly facilitates loss-of-function studies in models for which DNA-and RNA-based depletion methods are often ineffective, including nondividing primary cells. Third, Trim-Away is a protein-based depletion method and can be used in primary immune cells that have active nucleic acid-sensing machineries. Fourth, TRIM21 is widely expressed in most tissues. This means that it may often be possible to take advantage of endogenously produced protein and not rely on ectopic overexpression or introduction of recombinant protein. Fifth, TRIM21 does not have a cellular housekeeping function, in contrast to E3s such as von Hippel-Lindau that are typically used in PROTAC applications 25 . This means there is no competition for endogenous substrates and less likelihood that normal metabolism will be impacted. Last, Trim-Away uses off-the-shelf reagents for protein targeting. Antibodies have been produced for almost all proteins and are widely commercially available.
As with any technique, Trim-Away has limitations. One limitation is that Trim-Away depends on the intrinsic proteasome activity. Hence, the efficiency of Trim-Away may be compromised in certain cell types and/or at certain cell cycle stages accordingly. Because Trim-Away is a protein-targeting method, another limitation is that it is more challenging to evaluate off-targets as compared with gene-or mRNA-targeting methods. Thus, antibodies used for protein-targeting must be carefully selected and validated before use, as discussed in the 'Experimental design' section ('Antibody selection'). In addition, an antigen buried within the native protein or a target stably localized in a particular cellular compartment such as the nucleus will not be accessible for degradation by the antibody. But the latter case may be circumvented by the use of a smaller nanobody-Fc fusion 15 . Finally, the usefulness of Trim-Away may be limited in certain models such as intact tissues, in which it is challenging to deliver antibody by microinjection or electroporation. However, as there are intensive efforts to develop cell delivery reagents, it may become possible in the future to use TrimAway even in intact-tissue applications. An important potential limitation in Trim-Away is that TRIM21 both targets proteins for degradation and can activate innate immune signal transduction pathways such as NF-κB (ref. 26 ). This is because TRIM21 synthesizes K63-ubiquitin chains, which when released by the proteasomal DUB RPN11 act as immune second messengers 21 . Fortunately, 8 Spin down in a SS34 rotor at 20,000g for 40 min at 4°C. Carefully decant the supernatant. Proceed to Step 9 during centrifugation. 9 In the meantime, wash 10 ml of Ni-NTA agarose in 50 ml of PBS (pH 8.0). Spin at 2,000g for 3 min at room temperature and discard the supernatant. Repeat once. c CRITICAL STEP Centrifugation of Ni-NTA beads at higher speeds for longer time periods will compress the resin and reduce its binding capacity. 10 Add Ni-NTA agarose to the cleared supernatant from step 8 in centrifuge tubes, supplement with 10 mM imidazole and rotate to allow mixing at 4°C for~1 h. 11 Spin down the resin at 2,000g for 3 min at 4°C and discard the supernatant. 12 Resuspend the resin in 40 ml of wash buffer, re-spin and discard the supernatant. Repeat this step once. 13 Decant the washed resin into an empty gravity-flow column. Wash the resin in place with two bed volumes of wash buffer. 14 Elute the protein from the resin with wash buffer supplemented with 300 mM imidazole. 15 Analyze the eluted protein by SDS-PAGE to ensure that the purification has been successful. This should be visible as a single band running at 66 kDa following Coomassie staining (Fig. 2g) . If so, proceed to step 16. 16 Apply the eluted protein to an S200 gel filtration column equilibrated with 20 mM Tris (pH 8.0)-200 mM NaCl. Select the size of the S200 column depending on the volume of eluate and total amount of protein to be purified. Follow the manufacturer's guidelines for column capacity and flow rate. c CRITICAL STEP Eluted protein will not remain stable under a high concentration of imidazole for prolonged periods, so it must be immediately buffer-exchanged, desalted or gel-filtered into 20 mM Tris (pH 8.0)-200 mM NaCl. c CRITICAL STEP Soluble aggregated materials will elute in the void volume of the column and should be discarded. 17 Analyze the peak fractions by SDS-PAGE to ensure that the correct peak is collected and to determine which fractions should be combined. c CRITICAL STEP TRIM21 is an elongated molecule with a large Stokes radius; if molecular weight standards are used to guide fraction collection, then note that TRIM21 will behave as if it is a trimer (i.e., 3× its expected molecular weight (~165 kDa)) in an S200 gel filtration column. 18 Concentrate the combined fractions of TRIM21 using 50-kDa cutoff centrifugal filter units, prepare aliquots and snap-freeze them in liquid nitrogen. c CRITICAL STEP The protein solution should be carefully monitored during centrifugation and regularly mixed to prevent superconcentration at the cellulose membrane. j PAUSE POINT The purified protein can be stored at −80°C as long as no signs of protein degradation can be seen.
there is a high activation barrier for TRIM21 signaling, and NF-κB activation is highly sensitive to changes in antibody affinity, concentration and viral dose 27, 28 . For instance, in our Trim-Away experiment targeting IκBα for degradation, NF-κB was only weakly activated in control cells in which mTOR was depleted 15 . If activation of NF-κB is a concern during Trim-Away, this can be assayed for either through the use of an NF-κB-luciferase reporter or by qPCR for cytokine transcripts.
Experimental design
Antibody selection Similar to other antibody-based techniques, the specificity of the antibody is critical for a successful Trim-Away experiment. A good antibody should degrade all antigens bearing the targeted epitope (i.e., on-target) but not irrelevant antigens (i.e., off-target). When selecting an antibody for TrimAway, several parameters should be considered:
• Antibody species. The TRIM21-antibody interaction is highly conserved and maintained both within and between murine, canine, primate and human species 24 . Our preliminary results with anti-GFP antibodies raised in mouse, rabbit and goat suggest no substantial difference in their Trim-Away efficiency at the same concentration. We have also successfully used antibodies raised in rat 15 . However, antibodies from less common hosts such as guinea pig and sheep should be tested before actual application. TRIM21 does not bind to chicken antibodies.
• Isotype of antibody. TRIM21 has the highest affinity to IgG, followed by IgM and IgA 28 . Binding of TRIM21 to IgD or IgE remains unknown. TRIM21 does not bind to IgY.
• Form of antibody. Commercial antibodies are offered in different forms such as full-length Ig, Fab and Fab2. Because TRIM21 binds to the Fc-region of antibodies, Fab and Fab2 should be avoided.
Considering the growing supply of nanobodies, we have also successfully used a fusion between a nanobody and the Fc-region of human IgG1 for Trim-Away experiments 15 .
• Clonality of antibody. We have had success with both polyclonal and monoclonal antibodies. Because of lot variations between polyclonal antibodies, we recommend using monoclonal antibodies because they may yield more reproducible results.
• Antigen of antibody. The epitope should be accessible to the antibody under native conditions.
• Antibodies against post-translationally modified proteins. Our preliminary results suggest that TrimAway can also be used to selectively degrade proteins with post-translational modifications, as long as specific antibodies are available. However, these antibodies must be evaluated particularly carefully before use. For instance, we observed nonspecific binding of some polyclonal antibodies against phosphorylated kinetochore proteins to acentriolar microtubule-organizing centers, which are also enriched in phosphorylated proteins in mouse oocytes (and vice versa).
Antibody validation
Before proceeding to Trim-Away, we generally validate the antibody by performing at least two of the experiments listed below:
• Co-localization with the fluorescently tagged protein. Most proteins localize correctly when they are tagged with a fluorescent protein. To evaluate whether an antibody is specific, we compare the localization of the fluorescent protein with the pattern obtained by immunofluorescence using the antibody of interest. They should be identical. Exceptions to this are some long-lived proteins such as Rec8 and CenpA in mouse oocytes 22, 29 . These proteins are loaded correctly only during particular stages of development, which do not allow further incorporation or displacement by their fluorescent reporter afterward. In addition, comparison of the staining pattern with published data from other cell types is a useful way to test for specificity.
• Antibody delivery followed by immunofluorescence. To determine the ability of an antibody to recognize the target protein in live cells, we deliver the antibody by either microinjection or electroporation, and fix and stain with a secondary antibody. The delivered antibody should show the same localization pattern as the immunofluorescence of the target protein using a different antibody. It is also possible to fluorescently label the antibody in order to observe correct binding to the target protein in live cells 30 . However, in some cases, antibody delivery may cause target protein degradation via endogenous TRIM21 and/or cause target protein mislocalization due to the inhibitory effects of antibody binding. We therefore recommend traditional immunofluorescence as the preferred method to validate antibodies.
• Immunoprecipitation followed by western blotting. To determine the ability of an antibody to recognize the target protein in native conformation in cells, we perform immunoprecipitation on the whole-cell lysate in non-denaturing conditions. The specific antibody should enrich a single band corresponding to the target protein over background band(s) (if any) in western blot. We do not recommend assessing the antibody by performing western blotting alone, as that provides information on only the specific binding of the antibody to the denatured epitope.
• Cross-validation with other approaches. To test for specific binding of an antibody, when possible, we first deplete the target protein with other approaches such as genome-editing or RNAi. This is followed by immunofluorescence using the antibody of interest. Specific binding of the antibody is confirmed by a reduction in the signal relative to the control. Such validation may also be provided by some antibody suppliers.
• Peptide pre-incubation followed by immunofluorescence. To test for nonspecific binding of an antibody, we pre-incubate the antibody with the immunizing peptide before immunofluorescence (Box 3). The degree of background binding can be estimated by the level of signal retained after blocking specific binding of the antibody. We highly recommend this assay for post-translational-modification-specific antibodies.
Source of TRIM21
TRIM21 is widely expressed in most tissues 23 . This means that most cell types will contain endogenous TRIM21 protein, and this may be sufficient for Trim-Away to work simply by delivering an Reagent setup PBT. Add 1 g of PBS tablets and 5 ml of 10% (vol/vol) Triton X-100 solution to 95 ml of water. Store at 4°C until use (for up to 1 year). PBT-BSA. Add 1 g of PBS tablets, 5 ml of 10% (vol/vol) Triton X-100 solution and 10 ml of 30% (wt/vol) BSA solution to 85 ml of water. Store at 4°C until use (for up to 1 year). PBT-BSA To 20
6 Pre-clear the mixes from step 5 by centrifuging at 20,000g for 5 min at 4°C. 7 Incubate one sample with the precleared mix without peptide from step 4 (i.e., no-peptide control) and the other sample with the precleared mix with peptide from step 4 (i.e., peptide pre-incubated sample) overnight at 4°C. 8 Wash the samples in PBT-BSA for 5 min at room temperature (25°C) three times. 9 Incubate the samples with secondary antibodies diluted in PBT-BSA for 1 h at room temperature. 10 Wash the samples three times in PBT for 5 min at room temperature. 11 Image the samples in PBS. 12 Assess nonspecific bindings from the signal present in both the no-peptide control and peptide pre-incubated sample.
antibody to unmodified cells. Indeed, we have found that RPE-1 cells and primary macrophages contain sufficient endogenous TRIM21 for Trim-Away of several different target proteins 15 . Cell types can be screened for TRIM21 expression levels by RT-PCR or by western blotting using anti-TRIM21 antibodies (see the 'Reagents' section). The relative expression levels of TRIM21 can be compared with those of low-expressing cells (HEK293T) or high-expressing cells (RPE-1). As an initial Trim-Away experiment, we suggest delivering the antibody to the cells of interest and screening for target protein depletion. Depending on the cell type and relative expression levels of cellular TRIM21 and the target protein, antibody delivery alone may be sufficient for target protein depletion. If target protein depletion does not occur, or is incomplete, then methods for increasing cellular TRIM21 levels can be considered from among the following options:
• TRIM21 overexpression. In oocytes and early embryos, we found it necessary to overexpress TRIM21 for successful Trim-Away. In these cell types, microinjection of Trim21 mRNA is the recommended method. In bulk cell populations, it is important to ensure that all cells in the population overexpress TRIM21. To achieve this, we recommend generating stable cell lines as described in Box 1.
• Recombinant TRIM21 protein. For some cell types, particularly primary cells, it is not possible to generate stable cell lines overexpressing TRIM21. In this case, it may be preferable to co-deliver a recombinant TRIM21 protein together with an antibody. Recombinant TRIM21 protein can be readily produced from bacteria as described in Box 2. Bacterially produced proteins may contain bacterial contaminants that could perturb certain cell types, such as immune cells. In these cases, it may be preferable to purify TRIM21 from insect or mammalian cells.
Trim-Away by microinjection of oocytes and early embryos
In our initial study, we microinjected Trim21 mRNA into arrested germinal vesicle (GV) oocytes, and incubated the oocytes for expression and recovery for 3 h, followed by microinjection of the antibody 15 . Depending on the biological questions to be addressed, antibodies can be microinjected immediately before meiotic release or during meiosis. Although sequential injections can be mastered by scientists with extensive experience in micromanipulation, a significant reduction in oocyte survival and developmental rates is frequently observed for less experienced operators.
We have therefore developed a simplified protocol that involves single microinjection, which minimizes harm to the cells. Here, we present protocols for both hydraulic-and pressure-based microinjection systems. Hydraulic-based systems allow injection of a defined volume but require the use of mercury-filled needles 31 . Although it is challenging to consistently inject a defined volume using pressure-based systems, these systems are more widely available, do not involve mercury and allow more rapid microinjections. The new protocols offer several benefits. First, single microinjection improves survival and developmental rates to levels comparable to those of routine live-imaging experiments. Second, depletion starts immediately after microinjection as Trim21 mRNA is translated, which can be advantageous for early embryos that cannot be arrested at a particular stage of development. Last, target proteins that are expressed at high endogenous levels (which can take up to 3-4 h for full depletion) are more completely degraded before meiotic release, and phenotypes during early meiosis are more consistent between individual oocytes.
In addition, we optimized our protocol for preparing mRNAs encoding Trim21 and reporters for live-cell imaging with several modifications. First, the use of an anti-reverse cap analog (ARCA) yields transcripts that are all capped in the correct orientation at the 5′ end and, hence, have a higher translation efficiency than mRNAs that have been synthesized with a standard cap analog. Second, the increased ratio of cap analog and GTP relative to other NTPs enables the synthesis of transcripts of up to 12 kb at high yield. Finally, the incorporation of a column cleanup step removes all free nucleotides, allowing higher accuracy in determination of mRNA concentration and reproducibility in expression level.
Trim-Away by electroporation of primary cells and cell lines A successful Trim-Away experiment in bulk cell populations depends on efficient delivery of antibody to all the cells in a population. Antibodies are large molecules (~150 kDa) that cannot cross cell membranes. We initially tested antibody delivery by conventional chemical-and lipid-based transfection reagents in addition to several different commercially available protein and antibody transfection reagents. However, this most often led to antibodies being trapped inside intracellular vesicles with very little antibody actually reaching the cytosol. We also tested classic electroporation using conventional cuvettes. However, this caused high levels of cell death, and surviving cells tended to have morphological changes and exhibit antibodies stuck to the cell surface, trapped inside intracellular vesicles, and aggregated inside the cells. We and others have found that a new type of electroporation device with a capillary electrode 15, 30, 32, 33 , available commercially as the Neon Transfection System, can be used to deliver antibodies directly to the cytoplasm of almost 100% of cells without cell death. Cells are morphologically normal after electroporation with the Neon system and re-adhere and proliferate at a rate similar to that of non-electroporated cells 15 . Thus, Trim-Away experiments can be performed by electroporation of antibodies, and phenotypes can be analyzed as soon as the target protein is depleted, which is usually within 3 h. In addition, we found that efficient antibody delivery can also be achieved in primary cells such as normal human lung fibroblasts, mouse bone-marrow-derived macrophages and human monocyte-derived macrophages 15 . Here, we include an optimized antibody electroporation protocol that we found to be suitable for antibody delivery in all cell types tested so far.
Trim-Away controls
To properly interpret a Trim-Away experiment, certain controls can be included. To control for antibody delivery, we recommend using isotype control antibodies of the same clonality as the antibodies used for targeted protein degradation. Control antibodies are often raised against proteins that are not normally expressed in mammalian cells, such as GFP or yeast proteins, and are readily available from most antibody suppliers. Additional controls such as delivery of antibody buffer alone and non-electroporated/microinjected cells can also be included. If a Trim-Away experiment requires TRIM21 overexpression, we also recommend including non-overexpressing cells as an additional control. Importantly, we found that both antibody delivery and TRIM21 overexpression did not perturb cell proliferation or induce major changes in global transcript levels 15 .
Confirmation of protein depletion by Trim-Away
Confirmation of protein depletion by Trim-Away can be achieved by standard methods used to detect cellular levels of endogenous proteins. For example, immunofluorescence, flow-cytometry or western blotting methods are suitable. When using secondary antibody-based detection methods to detect cellular levels of target proteins after treatment with Trim-Away (and also other nontargeted cellular proteins), it is important to take into account that secondary antibodies will also detect residual electroporated/microinjected antibody present in the cell if the secondary antibodies are raised against the same species of antibody as the delivered antibody. This problem will arise if the antibody delivered to cells for Trim-Away is also used as a primary antibody for protein detection. When performing western blotting, this will result in detection of IgG heavy chain and light chain on the membrane (at~50 kDa and~25 kDa, respectively), which may interfere with detection of endogenous proteins. When performing immunofluorescence or flow cytometry, this will result in higher levels of background signal. In all detection methods, this problem can be avoided by using primary antibodies of a different species than the antibodies delivered to the cells for Trim-Away. If there is no option but to use the same antibody (or antibodies from the same species) for Trim-Away and for detection, HRP-conjugated secondary antibodies that bind only to the native non-denatured IgG can be used for western blotting, and primary antibodies can be directly labeled with fluorophores for immunofluorescence and flow cytometry.
Confirmation of specificity in a Trim-Away experiment
The specificity of depletion in a Trim-Away experiment is determined by the specificity of the antibody used. Thus, antibodies should be selected carefully, as described above (see 'Antibody selection'). If multiple antibodies raised against different regions of the same target protein are available, these can be used to confirm the specificity of a Trim-Away phenotype. Rescue experiments can also be performed by overexpressing exogenous target protein. When performing rescue experiments, it should be considered that the antibody delivered during Trim-Away will probably also target the exogenous protein for degradation. In this case, it may be necessary to increase expression levels of the exogenous protein in order to saturate the cellular antibody and TRIM21 to allow for a rescue. Similarly, the amount of delivered antibody should be minimized to aid rescue experiments. It may also be possible to rescue a phenotype by overexpressing exogenous protein from a different species that is not recognized by the antibody used for Trim-Away. Another way to confirm the specificity of depletion is to express a fluorescently tagged target protein. Upon acute delivery of the antibody against the target protein, the fluorescent signal should be reduced as a result of co-degradation of the fluorescent tag. • Primary cells of interest. We have used NHLF (Lonza, cat. no. CC2512), human monocyte-derived macrophages (from patient blood samples, derived as described in ref. 15 ) and mouse bone-marrowderived macrophages (derived as described in ref. 15 ), although any mammalian primary cells may be used. ! CAUTION Cell lines should be regularly checked to ensure that they are authentic and not infected with mycoplasma.
• Mouse anti-TRIM21 (D-12; Santa Cruz Biotechnology, cat. no. 
Reagent setup
Trim21 and reporter mRNA mRNAs encoding Trim21 and reporters for live-cell imaging such as meGFP-MAP4 and H2B-mCherry are prepared by in vitro transcription as described in Box 4 and can be stored at −80°C as long as no signs of mRNA degradation can be seen.
TRIM21-overexpressing stable cell lines TRIM21-overexpressing cell lines are prepared as described in Box 1 and can be cultivated at 37°C/5% CO 2 as long as no signs of senescence can be seen. Procedure 1 Linearization and purification of DNA template (steps [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Mix the components listed below in a 1.5-ml nuclease-free tube and incubate at 37°C for 1 h.
Component Amount per reaction (µl) Final concentration
Nuclease-free water 20 0.5 µg/µl Trim21 or reporter construct (in pGEMHE) 20 0.2 µg/µl 10× CutSmart buffer 5 1× 10 U/µl AscI 5 1 U / µl c CRITICAL STEP We generally use pGEMHE as the vector because it contains a T7 promoter, multiple cloning sites flanked by 5ʹ-and 3ʹ-untranslated regions (UTRs) of the Xenopus β-globin gene, a short stretch of (~35-bp) poly(A) sequence and linearization sites. Constructs in other vectors such as pCS2 can also be used, but the translation efficiency may be lower because of the lack of 5ʹ and 3ʹ UTRs, and poly(A) tailing may be required. 2 Add 0.5 µl of glycogen, 150 µl of nuclease-free water and 200 µl of phenol-chloroform-IAA (pH 8.0) to terminate the linearization reaction. c CRITICAL STEP Addition of glycogen as a co-precipitant is optional, but the yield of precipitated DNA is higher. c CRITICAL STEP Phenol-chloroform-IAA is saturated and stored with an equilibration buffer. Do not take in the upper aqueous layer to avoid dilution. 3 Invert end-to-end to mix well and centrifuge at 20,000g for 5 min at room temperature. 4 Transfer~180 µl of the upper phase to a new 1.5-ml nuclease-free tube, add 20 µl of 3 M sodium acetate (pH 7.0) and 400 µl of ice-cold 100% (vol/vol) ethanol. c CRITICAL STEP Do not use isopropanol, as more salts will be precipitated. 5 Invert end-to-end to mix well and snap-freeze in liquid nitrogen.
(continued) 6 Centrifuge at 20,000g for 30 min at 4°C. c CRITICAL STEP Start centrifugation before the mixture thaws. 7 Discard the supernatant and add 1 ml of ice-cold 70% (vol/vol) ethanol in nuclease-free water. 8 Invert end-to-end to mix well and centrifuge at 20,000g for 1 min at 4°C. c CRITICAL STEP Do not vortex, in order to avoid fragmentation of the pellet. 9 Discard~900 µl of the supernatant and centrifuge at 20,000g for 30 s at 4°C. c CRITICAL STEP This step is necessary for avoiding ethanol carryover. 10 Discard the rest of the supernatant and air-dry for 3 min at room temperature. c CRITICAL STEP After drying, the center of the pellet should remain white, with the edge being transparent. Over-drying, as indicated by a completely transparent pellet, should be avoided. 11 Add 6 µl of nuclease-free water and pipette up and down to fully dissolve the pellet. 12 Use 1 µl to measure the DNA concentration with a NanoDrop spectrophotometer. We typically recover 7-8 µg of linearized DNA. j PAUSE POINT Linearized DNA can be stored at −20°C for up to 1 week until use. 13 In vitro transcription of capped mRNA (step 13). Mix the components listed below in a 1.5-ml nuclease-free tube and incubate at 40°C for 4 h. c CRITICAL STEP We generally omit steps 15 and 16 when we synthesize mRNAs from pGEMHE-based plasmids, and instead add 237 µl of nuclease-free water and directly proceed to step 17. However, poly(A) tailing can be advantageous for assays with a longer time frame (i.e., >24 h) or for mRNAs transcribed from constructs without a short stretch of poly(A) tail. 16 Add 15 µl of poly(A) polymerase and incubate at 37°C for 30 min. 17 Removal of free nucleotides (step 17). Purify the mRNA using NucleoSpin RNA Clean-up XS and elute with 160 µl of nuclease-free water. c CRITICAL STEP This step can be omitted, but then the final RNA concentration cannot be directly determined with a NanoDrop spectrophotometer because of free-nucleotide contamination. . c CRITICAL STEP Addition of glycogen as a co-precipitant is optional, but the yield of precipitated mRNA is higher. c CRITICAL STEP Phenol-chloroform-IAA is saturated and stored with an equilibration buffer. Do not take in the upper aqueous layer to avoid dilution. 19 Invert end-to-end to mix well and centrifuge at 20,000g for 5 min at room temperature. 20 Transfer~180 µl of the upper phase to a new 1.5-ml nuclease-free tube and add 360 µl of ice-cold 100% (vol/vol) ethanol. c CRITICAL STEP Do not use 100% isopropanol, as more salts will be precipitated. 21 Repeat steps 5-10. 22 Add 11 µl of nuclease-free water and pipette up and down to fully dissolve the pellet. 23 Use 1 µl to measure the RNA concentration with a NanoDrop spectrophotometer. c CRITICAL STEP RNA concentration can also be determined with other techniques such as agarose gel electrophoresis and comparison with RNA markers of known concentration or fluorescence-based Qubit RNA assays. c CRITICAL STEP We typically obtain mRNA at~1-3 µg/µl. j PAUSE POINT mRNA should be divided into 0.6-µl single-use aliquots and can be stored at −80°C as long as no signs of mRNA degradation can be seen.
Box 4 | (continued)
PROTOCOL
NATURE PROTOCOLS
Recombinant TRIM21 protein TRIM21 protein is prepared by purification from bacteria as described in Box 2 and can be stored at −80°C as long as no signs of protein degradation can be seen.
PBS for antibody preparation
Dissolve 5 g of PBS tablets in 500 ml of embryo-tested or nuclease-free water. Store at room temperature as long as no signs of contamination can be seen.
Homemade culture medium for isolating mouse oocytes and pre-implantation embryos We routinely use modified M2 medium as described in ref. 34 c CRITICAL Drugs such as 250 μM dibutyryl cyclic adenosine monophosphate should be added to the culture medium to maintain meiotic arrest for GV oocytes.
DMEM supplemented with 1× GlutaMAX and 10% (vol/vol) FBS Add 55 ml of FBS to 500 ml of DMEM. Store at 4°C for up to 1 year from the date of manufacture until use.
Equipment setup
Mouth pipette for isolation and culture of mouse oocytes and pre-implantation embryos Pull microcapillary tubes above a gas burner. Break the tip by striking a pair of pipettes against each other to obtain a smooth opening of~80-100 μm. Attach a pipette to the aspirator tube assembly. More details on mouth pipettes can be found in ref. 35 .
Microinjection setup
Install the inverted microscope on a vibration-free table. For the use of hydraulics-based systems, mount the coarse manipulator and the three-axis joystick oil hydraulic micromanipulator on one side of the arm. For the use of pressure-based systems, install the Adapter Zeiss 2 and mount a TransferMan 4r on both sides of the arm.
Coverslips
Boil 0.5 liter of deionized water in a microwave oven, add a few drops of dishwashing detergent and add 22 × 22 mm no. 0 glass coverslips one by one. Incubate for 20 min at room temperature and discard the detergent solution. Rinse with deionized water three times, boil and rinse with deionized water three times again. Transfer the coverslips one by one to 0.5 liter of 5 M hydrochloric acid and incubate overnight at room temperature. Rinse five times with deionized water and three times with double-distilled water. Transfer the coverslips one by one to 70% (vol/vol) ethanol for storage. Blotdry excess ethanol solution and air-dry before use. c CRITICAL Using unwashed coverslips for microinjection may compromise the survival rate of oocytes and early embryos during microinjection.
Microinjection chamber
Cut a washed coverslip along the edges into six equal rectangular pieces (shelves) and a center square piece with a diamond pencil. Attach a piece of double-sided tape of approximately the same dimensions as a shelf (as a spacer of~100 μm) close to the center of another washed coverslip at 5 mm from one edge. Attach a shelf to the double-sided tape to form an~0.5-mm loading space at the side closest to the edge. Apply a thin layer of silicon grease along the U-shaped cut on both sides of the microinjection chamber. Attach the coverslip, with the loading space facing away from the U-shaped cut, to the side of the microinjection chamber with a groove for placing the capillary. Attach another washed coverslip to the other side of the microinjection chamber. Gently press on the coverslips to spread the silicon grease. Fill the U-shaped reservoir with culture medium, and keep the microinjection chamber in a humidified container at 37°C before use. After loading and before microinjection, apply a thin layer of silicon grease along the groove and insert the capillary with mRNA and/or antibody.
Microinjection needle
Siliconize the microcaps by dipping one end into a beaker containing~0.5 cm of Sigmacote. A column of Sigmacote will form as a result of capillary action. Invert the microcaps end to end several times so that the entire length is fully covered with Sigmacote. Blot-dry excess Sigmacote at one end and air-dry for at least 2 weeks. Pull siliconized microcaps in a Flaming/Brown micropipette puller to obtain pairs of pipettes with an opening of~0.5-1 μm after breaking the tip. Back-load~1 µl of mercury as close to the tip as possible with a 10-µl calibrated syringe. c CRITICAL Siliconizing the microcaps largely facilitates the flow of mercury within the microinjection needle.
c CRITICAL Insufficient drying of Sigmacote increases the chance of breaking the mercury column during microinjection.
CellTram oil
Set up the CellTram Oil according to the manufacturer's instructions. Fill it with mineral oil.
FemtoJet 4i
Set up the FemtoJet 4i according to the manufacturer's instructions.
CellTram Air
Set up the CellTram Air according to the manufacturer's instructions.
Neon Transfection System for electroporation in primary cells and cell lines
The Neon Transfection System should be set up according to the manufacturer's instructions.
Procedure
Antibody preparation for Trim-Away • Timing 1-2 h c CRITICAL This section describes how to prepare the antibody of interest for Trim-Away. Ultrafiltration is necessary for removing contaminants that are cytotoxic (e.g., sodium azide) or interfere with microinjection (e.g., glycerol). 1 If the antibody is from an unpurified source such as serum, ascites fluid or cell culture supernatant, or contains BSA or gelatin, pre-purify the antibody using the 0.2-ml NAb protein A/G Spin Kit. c CRITICAL STEP This step is necessary for removing contaminating proteins, which lead to an overestimation of the IgG concentration. Gelatin is not compatible with the Amicon Ultra-0.5 100-K devices used in Step 3. 2 Mix the components listed below in a 1.5-ml nuclease-free tube on ice.
Component Amount per reaction (µl) Final concentration
PBS (in embryo-tested or nuclease-free water) 400-450 1 mg/ml antibody 50-100 0.1-0.2 µg/µl c CRITICAL STEP For co-injection of Trim21 mRNA and antibody using FemtoJet, PBS should be prepared in nuclease-free water instead to reduce the chance of RNase contamination. 3 Insert an Amicon Ultra-0.5 100-K device into a provided collection tube. 4 Apply 500 µl of diluted antibody from Step 2 to the device. 5 Align the cap strap of the collection tube and the membrane of the device toward the center of the rotor. 6 Centrifuge at 14,000g for 10 min at 4°C. c CRITICAL STEP Higher centrifugal force may damage the membrane and cause sample loss. 7 Discard the flow-through. 8 Add 480 µl of PBS to the Amicon Ultra-0.5 100-K device and carefully mix well. c CRITICAL STEP Mixing is necessary to avoid a high local concentration during ultrafiltration, which can cause protein aggregation and loss. Avoid touching the membrane with the pipette tip, as this may damage the membrane and cause sample loss.
9 Repeat Steps 5-7 twice.
? TROUBLESHOOTING 10 Insert the inverted Amicon Ultra-0.5 100-K device into another provided collection tube.
11 Align the open cap toward the center of the rotor. 12 Centrifuge at 1,000g for 2 min at 4°C. 13 Use 2 µl to measure the IgG concentration with a NanoDrop spectrophotometer. c CRITICAL STEP 1.0 OD 280 is equivalent to 0.714 mg/ml IgG. c CRITICAL STEP We typically retrieve~20 µl of purified antibody at~1.25-2.5 mg/ml from 50 µg of input. ? TROUBLESHOOTING 14 Snap-freeze in liquid nitrogen. c CRITICAL STEP The purified antibody should be divided into 1-to 2-µl single-use aliquots to minimize freeze-thaw cycles in the absence of cryoprotectant. j PAUSE POINT The antibody can be stored at −80°C as long as no loss of activity can be seen.
Isolation and culture of mouse oocytes and pre-implantation embryos • Timing >1 h 15 Isolate and culture mouse GV, meiosis II (MII) oocytes or early embryos in oil as previously described in refs. [36] [37] [38] [39] [40] [41] .
Trim-Away by microinjection of mouse oocytes and pre-implantation embryos • Timing 4-5 h
16 To perform constitutive depletion (Fig. 3a) using hydraulic systems, follow option A. To perform constitutive depletion using pressure-based systems, follow option B. To perform acute depletion (Fig. 3b) , follow option C. j PAUSE POINT The mRNA mix can be stored at −20°C or −80°C (for up to 1 year) until use. We usually freeze-thaw the mRNA mix up to four times without noticeable RNA degradation.
(ii) Mix the components listed below in another 1.5-ml nuclease-free tube on ice. c CRITICAL STEP Antibody at a final concentration of 1 mg/ml is a good starting point for complete depletion of most target proteins. However, we suggest titrating individual antibodies to the minimal effective concentration, as some can have secondary inhibitory effects. c CRITICAL STEP For antibody at a final concentration of <0.1 mg/ml, storage in a lowprotein-binding tube or preparation of fresh antibody mix is recommended. c CRITICAL STEP NP-40 largely facilitates the flow of the viscous antibody mix within the microinjection needle and reduces the chance of clogging. j PAUSE POINT For short-term storage (up to 1 week), the antibody mix can be stored at 4°C in a 1.5-ml tube with the opening sealed with Parafilm. However, changes in ionic strength due to repeated evaporation and condensation at the cap can denature the antibody/antibodies. For long-term storage (up to at least 1 month), the antibody mix can 7 pl by first microinjecting different amounts of a fluorescent dye into oocytes or early embryos and measuring the intracellular fluorescence intensity and the fluorescence intensity of a series of dye solutions of known concentration. The injection volume can then be calculated using the formula F dye injected × V dye injected = F cell × V cell , in which F dye injected and V dye injected are the fluorescence intensity and volume of the dye solution microinjected, respectively, and F cell and V cell are the fluorescence intensity and volume of the oocyte or early embryo microinjected, respectively. More details can be found in refs. 42 and 43 . c CRITICAL STEP This step depends on the experience of the scientist and may be optional. c CRITICAL STEP The mRNA and antibody mix can be injected at a volume of up to 12 pl without harming the oocytes, which may be necessary for antibody/antibodies that cannot be concentrated to the desired concentration. (ix) Adjust the level of the holding capillary until the oocyte or early embryo is in focus.
? TROUBLESHOOTING (x) Secure an oocyte or early embryo in place by applying a negative pressure at the holding capillary. c CRITICAL STEP The supernatant should be removed carefully, using a Gilson pipette, to avoid disturbing the cell pellet and subsequent cell loss. 26 Resuspend the cell pellet in n × 10 µl of Neon Buffer R (where n = number of electroporation reactions). c CRITICAL STEP Once the cells are resuspended in Neon Buffer R, it is important to proceed with electroporation immediately. Prolonged incubation (>30 min) in Neon Buffer R can reduce cell viability. 27 Add 10.5 µl (~8 × 10 5 ) of cells per electroporation reaction to 1.5-ml tubes. c CRITICAL STEP It is important to avoid introducing air bubbles, which can cause arcing during electroporation.
28 Add 2 µl of antibody from Step 14 to the cells and mix gently. c CRITICAL STEP Antibody at a concentration of 1 mg/ml is a good starting point for complete depletion of most target proteins. However, we suggest titrating individual antibodies to the minimal effective concentration, as some can have secondary inhibitory effects. c CRITICAL STEP It is important to avoid introducing air bubbles, which can cause arcing during electroporation. Gently tapping the tube can help to remove any air bubbles. A total volume of 12.5 µl per electroporation reaction should be used, as this helps prevent any air bubbles being taken up into the 10-µl Neon Tip in Step 28. 29 Take up the cell/antibody mix into the 10-µl Neon Tip. c CRITICAL STEP It is essential to avoid taking up air bubbles into the 10-µl Neon Tip, as these can cause arcing during electroporation. Using a single smooth pipetting action combined with gentle swirling is recommended. Avoid pipetting up and down. For detailed instructions on how to insert the 10-µl Neon Tip into the Neon Pipette, refer to the Neon Transfection System manual (https://tools.thermofisher.com/content/sfs/manuals/neon_device_man.pdf). ? TROUBLESHOOTING 30 Insert the Neon Pipette with the sample in the tip into the Neon Tube containing 3 ml of Neon Buffer E assembled in the Neon Pipette Station. Push down vertically until a click is heard. 31 Electroporate using the following parameters: 1,400 V, two pulses, 20 ms per pulse. c CRITICAL STEP If there is a visible spark, discard the sample and return to Step 28. 32 Transfer the sample to a 1.5-ml tube containing 1 ml of prewarmed cell growth medium without antibiotics. Electroporated cells can now be plated as determined by the scientist. An incubation time of~3 h is usually sufficient for target protein degradation. ? TROUBLESHOOTING
Troubleshooting
Troubleshooting advice can be found in Table 1 . (Figs. 3d and 4b) , confirming the specificity of Eg5 depletion by Trim-Away.
Reporting Summary
Further information on experimental design is available in the Nature Research Reporting Summary linked to this article. 
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested 
Data analysis
Provide a description of all commercial and custom code used to analyse the data in this study, specifying the version used OR state that no software was used.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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